After a successful six-month tenure as interim CEO and COO, Dr Hazel Jones took over the Position of CEO. Dr Chris Torrance, Chairman of the Board of Directors, Enhanc3D Genomics, said: “We're thrilled to officially appoint Hazel as CEO. Her guidance as COO and interim CEO has been instrumental in driving Enhanc3D Genomics’ global operations, forming new connections and developing existing strategic partnerships. On behalf of the Board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the Company.”

As COO and interim CEO Hazel has overseen the Company's global business operations and held responsibility for executing its strategic vision for commercial and academic partnerships. She has played a leading role in transitioning the Company's 3D genomics platform from development to practical application in R&D.